Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03197688 · ClinicalTrials.gov registry record
Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States
A clinical trial, sponsored by Actelion.
- Completed
- Registry status
- 2,200
- Enrollment target
NCT03197688 is a clinical trial that has completed, run by Actelion. The registered enrollment target is 2,200 participants.
The verdict
NCT03197688 has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- 2,200 participants
- Enrollment target
Study Summary
The Opsumit Users registry (OPUS; NCT02126943) was developed to characterize the safety profile of Opsumit and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting. It is expected that the recruitment target of the OPUS registry cannot be achieved within the planned time period (5000 Opsumit new users by October 2018). The OrPHeUS study is designed to supplement the OPUS registry with retrospectively identified first-time Opsumit users in order to achieve the desired sample size.
Interventions
- OTHER Notapplicable
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,200 participants |
| Start Date | 2017-08-03 |
| Est. Completion | 2018-09-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03197688
The ClinicalTrials.gov registry entry for NCT03197688 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Notapplicable is the first listed.
NCT03197688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03197688 about?
NCT03197688 is a clinical study titled "Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States". The Opsumit Users registry (OPUS; NCT02126943) was developed to characterize the safety profile of Opsumit and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting. It is expected that the recruitment target of the OPUS registry canno...
What is the current status of trial NCT03197688?
This trial is currently completed. The enrollment target is 2,200 participants. The study started on 2017-08-03. Estimated completion is 2018-09-06.
What interventions are being tested in trial NCT03197688?
The interventions under investigation include: Notapplicable (OTHER).
Who is sponsoring clinical trial NCT03197688?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.